Priavoid

Priavoid is a clinical-stage biotech pioneering a unique 'detangler' approach to treat neurodegenerative diseases by disassembling neurotoxic protein aggregates. Its proprietary platform generates all-D-peptides, which are orally available, non-immunogenic, and can reach targets in the brain. The pipeline includes a Phase 2 candidate for Alzheimer's (PRI-002), a program for synucleinopathies like Parkinson's (PRI-101), and a preclinical tau-targeting program (PRI-200), positioning the company at the forefront of a novel therapeutic modality for these challenging conditions.

Proprietary 'detangler' platform for developing orally available, non-immunogenic all-D-peptides designed to specifically bind to, inhibit, and reverse the assembly of neurotoxic protein aggregates in the brain.

Priavoid competes in the crowded neurodegenerative disease space against large pharma companies developing monoclonal antibodies (e.g., Eisai/Biogen's lecanemab, Lilly's donanemab), small molecules, and other modalities. Its key differentiation is the oral administration and direct 'detangling' mechanism of its all-D-peptides, contrasting with the peripheral clearance or immunotherapeutic approaches of many competitors.